Ask AI

Cases of Confounding Cholestasis: Navigating the Diagnostic and Therapeutic Challenges of PFICs

Progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS) are rare, heritable cholestatic liver diseases that lead to a range of hepatic and systemic effects, including hallmark cholestatic pruritus. Although PFIC and ALGS have typically been identified in pediatric settings, it is increasingly evident that they can present across the lifespan, and late-onset disease poses particular care challenges. Access expert-written ClinicalThought commentaries, downloadable slides, and an on-demand webcast to learn how to recognize patients who should be assessed for late-onset genetic cholestasis, incorporate systematic genetic testing in the evaluation process, and develop individualized treatment plans for patients with PFIC that prioritize symptom management and long-term management.

Share

Program Content

Events

Activities

Confounding cholestasis considerations
Confounding Cholestasis: Considerations for the Assessment of Late-Onset Disease
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 29, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Progressive Familial Intrahepatic Cholestasis (PFIC) Network.

Supporters

This activity is supported by Ipsen Biopharmaceuticals, Inc

Ipsen Biopharmaceuticals Inc

Partners

Progressive Familial Intrahepatic Cholestasis (PFIC) Network

ProCE Banner